Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 4/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25376559 | 0.89 | POLB (0.55) | POLBSMN1; SMN2HRH3KMT2AMEN1 | |
| SCHEMBL30552687 | 0.82 | POLB (0.59) | POLBSMN1; SMN2HRH3KMT2AMEN1 | |
| SCHEMBL31428828 | 0.82 | POLB (0.59) | POLBSMN1; SMN2HRH3KMT2AMEN1 | |
| SCHEMBL25431128 | 0.82 | POLB (0.59) | POLBSMN1; SMN2HRH3KMT2AMEN1 | |
| SCHEMBL31428559 | 0.81 | POLB (0.56) | POLBSMN1; SMN2HRH3KMT2AMEN1 | |
| SCHEMBL31428832 | 0.74 | RAB9A (0.55) | POLBSMN1; SMN2KMT2AMEN1HRH4 | |
| SCHEMBL2770082 | 0.73 | HRH4 (0.71) | POLBSMN1; SMN2HRH3KMT2AHRH4 | |
| SCHEMBL3369566 | 0.72 | HRH4 (0.59) | POLBSMN1; SMN2HRH3KMT2AMEN1 | |
| SCHEMBL3253717 | 0.72 | POLB (1.00) | POLBSMN1; SMN2HRH3HRH4AKR1C3 | |
| SCHEMBL1612954 | 0.72 | HRH3 (0.72) | POLBSMN1; SMN2HRH3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
| WO-2023008577-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | 国立大学法人神戸大学 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | POLB 3285/4885SMN1; SMN2 4832/4885HRH3 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.